How to Approach a Patient with Limited Stage Hodgkin Lymphoma Who Remains PET Positive at the End of Chemotherapy: Radiation Therapy?

Publication date: Available online 29 June 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Nmazuo W. Ozuah, Ann S. LaCasce The use of 18 F-fluorodeoxyglucose positron emission tomography with computerized tomography (FDG-PET/CT), has emerged as a crucial tool for response-adapted therapy in Hodgkin lymphoma (HL). Although more studies have focused on the predictive value of an interim or early PET obtained after 2 cycles of chemotherapy, there are indications that the end of therapy PET may even be more predictive of outcome. The optimal treatment of patients with limited stage HL who are PET positive after chemotherapy is unknown. Here we review the prognostic significance of end of treatment PET in early stage HL, the role of consolidative radiotherapy in patients who have FDG-PET avidity at the end of chemotherapy, and discuss the place of salvage chemotherapy and autologous transplantation in these patients.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research